RCS - Genflow Biosciences - Launch of AI-Powered Partnership

Genflow BiosciencesAnnouncement

14/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250414:nRSN7586Ea&default-theme=true

RNS Number : 7586E  Genflow Biosciences PLC  14 April 2025

14 April 2025

 

Genflow Biosciences Plc

Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered
Partnership in Gene Therapy Research

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
the only publicly listed longevity company in Europe, is pleased to announce
that, in addition to the recently announced launch of a new development
program in ophthalmology, it has entered into a strategic partnership with
Heureka Labs, Inc., a U.S.-based AI-driven discovery and analytics platform.

 

A Master Services Agreement ("MSA") was signed by both parties on 11 April
2025, establishing a framework for long-term collaboration.

 

Under the terms of the MSA, Heureka Labs, a technology spin-off from Duke
University, will provide Genflow with access to its proprietary artificial
intelligence ("AI") platform, which specializes in the analysis of
high-dimensional genomic data including RNA sequencing and gene expression
profiles. The application of Heureka's AI technology is expected to enhance
Genflow's ability to interpret complex biological datasets, enabling deeper
insights into gene regulatory networks and systemic biological responses.
These insights will be key to optimising therapeutic design and anticipating
patient-specific outcomes. Genflow will retain all IP rights under the MSA.

 

Initial efforts will support the Company's lead candidate, GF-1002, a
centenarian SIRT6-based gene therapy currently in preclinical evaluation and
may extend to future pipeline gene therapy programs, including those targeting
Metabolic Dysfunction-Associated Steatohepatitis ("MASH").

 

Heureka's AI platform is designed to accelerate drug discovery processes by
generating testable hypotheses, uncovering unexpected biological patterns, and
improving the efficiency of research and development workflows. The platform
is currently in use by leading pharmaceutical and biotechnology companies.

 

"Incorporating AI is no longer optional in bioinformatics research-it's
essential for precision, speed, and scale," said Dr. Eric Leire, CEO of
Genflow. "Heureka's AI platform gives us the tools to navigate complex
biological data and refine our gene therapy approach across a number of
programs we are working on, accelerating the delivery of safe and effective
therapies that promote a healthier lifespan, while helping to ease the growing
operational and economic burden of an aging population."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 0203 821 6168

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs planned for 2025, include a clinical trial that will explore the
potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKDBNNBKDNQD